HRP20191862T1 - Procjena rizika u liječenju antibioticima kod pacijenata koji boluju od primarne nezarazne bolesti određivanjem razine prokalcitonina - Google Patents

Procjena rizika u liječenju antibioticima kod pacijenata koji boluju od primarne nezarazne bolesti određivanjem razine prokalcitonina Download PDF

Info

Publication number
HRP20191862T1
HRP20191862T1 HRP20191862TT HRP20191862T HRP20191862T1 HR P20191862 T1 HRP20191862 T1 HR P20191862T1 HR P20191862T T HRP20191862T T HR P20191862TT HR P20191862 T HRP20191862 T HR P20191862T HR P20191862 T1 HRP20191862 T1 HR P20191862T1
Authority
HR
Croatia
Prior art keywords
disease
antibiotics
fragment
vitro diagnostic
caused
Prior art date
Application number
HRP20191862TT
Other languages
English (en)
Croatian (hr)
Inventor
Andreas Bergmann
Joachim Struck
Original Assignee
B.R.A.H.M.S Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40886944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191862(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by B.R.A.H.M.S Gmbh filed Critical B.R.A.H.M.S Gmbh
Publication of HRP20191862T1 publication Critical patent/HRP20191862T1/hr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/585Calcitonins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/325Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20191862TT 2009-04-14 2010-04-14 Procjena rizika u liječenju antibioticima kod pacijenata koji boluju od primarne nezarazne bolesti određivanjem razine prokalcitonina HRP20191862T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09157886 2009-04-14
PCT/EP2010/002279 WO2010118855A1 (en) 2009-04-14 2010-04-14 Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
EP10717531.7A EP2419741B1 (en) 2009-04-14 2010-04-14 Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin

Publications (1)

Publication Number Publication Date
HRP20191862T1 true HRP20191862T1 (hr) 2019-12-27

Family

ID=40886944

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191862TT HRP20191862T1 (hr) 2009-04-14 2010-04-14 Procjena rizika u liječenju antibioticima kod pacijenata koji boluju od primarne nezarazne bolesti određivanjem razine prokalcitonina

Country Status (15)

Country Link
US (3) US9046532B2 (https=)
EP (1) EP2419741B1 (https=)
JP (1) JP5650718B2 (https=)
CN (2) CN105334330A (https=)
CY (1) CY1122202T1 (https=)
DK (1) DK2419741T3 (https=)
ES (1) ES2751105T3 (https=)
HK (1) HK1221766A1 (https=)
HR (1) HRP20191862T1 (https=)
HU (1) HUE046182T2 (https=)
LT (1) LT2419741T (https=)
PL (1) PL2419741T3 (https=)
PT (1) PT2419741T (https=)
SI (1) SI2419741T1 (https=)
WO (1) WO2010118855A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836841B1 (en) * 2012-04-12 2022-01-05 B.R.A.H.M.S GmbH Prognosis of adverse events in patients with suspected chronic heart failure
CN105528511A (zh) * 2014-10-25 2016-04-27 潘一琦 一种远程诊疗对比式问诊方法及其系统
CN107301319B (zh) * 2017-06-26 2021-02-26 济南市儿童医院 儿科临床及科研中抗菌药物使用危险评估系统
JP7444776B2 (ja) * 2017-12-20 2024-03-06 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 併存症を有する患者におけるプロカルシトニンに基づく抗生物質療法のガイダンス
EP3502706A1 (en) * 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
DE19600875C1 (de) * 1996-01-12 1997-06-26 Brahms Diagnostica Gmbh Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse
ATE395364T1 (de) * 1999-12-22 2008-05-15 Dade Behring Marburg Gmbh Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung
JP2005522669A (ja) * 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
DE102005034174A1 (de) * 2005-07-21 2007-02-08 B.R.A.H.M.S Ag Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen
FR2894675B1 (fr) * 2005-12-14 2008-06-27 Assist Publ Hopitaux De Paris Distinction des meningites bacteriennes et virales
DE102006046996A1 (de) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
CN103123359B (zh) * 2007-08-03 2015-07-29 B.R.A.H.M.S有限公司 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用

Also Published As

Publication number Publication date
HK1221766A1 (zh) 2017-06-09
WO2010118855A1 (en) 2010-10-21
EP2419741A1 (en) 2012-02-22
HUE046182T2 (hu) 2020-02-28
CN102395888B (zh) 2017-05-03
PL2419741T3 (pl) 2020-01-31
JP2012523573A (ja) 2012-10-04
CY1122202T1 (el) 2020-11-25
LT2419741T (lt) 2019-11-11
EP2419741B1 (en) 2019-07-31
US9810699B2 (en) 2017-11-07
DK2419741T3 (da) 2019-11-04
JP5650718B2 (ja) 2015-01-07
US20180052179A1 (en) 2018-02-22
US20120100635A1 (en) 2012-04-26
US20150247871A1 (en) 2015-09-03
ES2751105T3 (es) 2020-03-30
US9046532B2 (en) 2015-06-02
SI2419741T1 (sl) 2019-12-31
PT2419741T (pt) 2019-11-04
CN105334330A (zh) 2016-02-17
CN102395888A (zh) 2012-03-28

Similar Documents

Publication Publication Date Title
US11241395B2 (en) Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease
CN104755930B (zh) 用于检测分析物的装置和方法
CN101568833B (zh) 使用MR-proADM的糖尿病诊断和风险分级
US11041867B2 (en) ProADM and/or histones as markers indicating an adverse event
JP2025019061A (ja) 術後有害事象の診断または予後
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
CN113176411B (zh) 利用唾液检测新型冠状病毒感染的生物标志物及其应用
HRP20191862T1 (hr) Procjena rizika u liječenju antibioticima kod pacijenata koji boluju od primarne nezarazne bolesti određivanjem razine prokalcitonina
EP3497450B1 (en) Histones and/or proadm as markers indicating organ dysfunction
WO2013090811A1 (en) Biomarkers of pulmonary hypertension
JP2024023615A (ja) 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのpro-adm
FI3356826T3 (fi) Gdf-15 melanooman diagnostisena markkerina
JP2023095851A (ja) 抗生物質治療をモニタリングするためのマーカーとしてのpctおよびpro-adm
JP2023041741A (ja) 重篤患者用の療法モニタリングマーカーとしてのpro-adm
Chaudhury et al. Procalcitonin in sepsis and bacterial infections
JP2012523573A5 (https=)
RU2009146803A (ru) Способ диагностики деструктивного панкреатита
Hu et al. Prognostic value of adrenomedullin and natriuretic peptides in uroseptic patients induced by ureteroscopy
WO2014108397A4 (en) A method for predicting the risk of getting cancer or diagnosing cancer in a subject
RU2788885C2 (ru) Прокальцитонин и про-адм в качестве маркеров для мониторинга лечения антибиотиками
TWI808323B (zh) Lama2, plxdc2及mll4作為檢測和識別糖尿病前期和糖尿病的新型生物標記的方法及用途
US20230093131A1 (en) Assessing and treating alcohol-associated liver disease
WO2025133235A1 (en) Adm-gly as marker for early predicting sepsis
CN100543471C (zh) 组织缺氧的体液指标
Mohammed et al. Obestatin/Ghrelin Ratio as a New Activity Index in Ulcerative Colitis